Thank Earnings to Chief joined Call. Fourth Organogenesis the you, Francisco, on Conference Dave today call by I'm Financial Fiscal Year Officer. and operator, our welcome, Quarter everyone, XXXX Holdings
XXXX, for our open then developments and this a as our results Let recent will condition the provide begin and our financial months. which in-depth prepared an for review with with well what quarter on balance me at remarks. in we call start an brief our revenue provide end results, we'll you update with operating I'll fourth sheet Dave our our an guidance of in agenda afternoon, as cover strategic up press and introduced quarter we during financial will questions. overview quarter fourth release then of financial key and of
on our our the results end XX% growing the third sales outlined in review above revenue QX, quarter for period. a of with guidance the high of call, range Beginning results we delivered
and customer guidance Our strong fourth quarter excess our reflect results in assumed. demand underlying business of trends what momentum in had
our on quarter XXXX in announced the recent fourth LCDs effective MACs expectation guidance ruling the the discussed finalized an As fourth calls, fiscal quarter was our be The that the proposed XXXX. of and in the reflected from in date would January with year investor final quarter. the LCD fourth X,
is of effective the experienced the However, of believe we related February later less XXXX, we the demand of stronger ruling from the delayed date XX, second in was in than had the the the LCD disruption result final assumed. a customer direct date fourth quarter marketplace half MAC. stated the for We effective to
the As substitute for mentioned previous for continuing clinical to we MACs products. earnings on demonstrated skin with efficacy calls, coverage prioritize applaud
clinical LCDs pushing substitute many we the for data. providing been up have skin approach of evidence-based all the We coverage said, believe to MAC years That access real-world both a reform marketplace and substantial and to should and forward represent who first step the for products the care. cleaning include need believe continue to toward
Importantly, we policies to the to for skin continue for changes introduce as to CMS requisite push well. the substitutes payment
value-based methodology, per outcomes the enable square CMS Part last the value-based treatment fixed substantially patient needs to basis. a substitute payment we patient individual B to health expenditures, for care access, a the physicians As communicated on has provide call, based options best to of potential and where system. should in patients Medicare paid reduce improve transition on the the prescribe that they methodology are to earnings discussed have categories payment centimeter our This skin on
current market, and with the CMS changes engage to advocate to continue this in the have will requisite leader for actively been a As we to system.
the We in market. fourth equity, were in innovative substantial the positioned we deep believe We news strong results are informed represent on together continue further both team's strong our represent Organogenesis' the relationships infrastructure reacted evidence to and focused better-than-expected commercial that quarter effective this and through navigate quarter. delivered proud quickly highly of established full the we treat and ensuring as to customer of taken to fourth customers date the They patients revenue brand advantage competitive and a products. uncertain our execution move with portfolio well delayed of the our
decision and XXXX, on more date support of for our behavior, LCDs ambiguity in has to customers challenging I'll later the XXXX. now, service focused call, XX, our on team January delay targeted second discuss and XX, excellent detail environment commercial customer say more guidance MACs news which but on this announced strategy and for our until that environment. our in providing the the Dave resulted dynamic created this the implementation in operating disruption On additional in the an a The of April XXXX. in is will in
have guidance on assuming XXXX, that effective final XX, LCD be We will financial introduced the our XXXX. for April
are and to experiences prior policies. new discussed customers reimbursement when the As calls, disruption implemented, trends in transition business on as demand the changes coverage and utilization
Apligraf take both skin apply products. our first Based affinity in reminder, of the environment third by an quarter. DFU a scheduled, VLU products for products in a such, in VLU on as remain stabilization substitute our in XX indications XXXX would date, and only business products of Dermagraft to the the way NuShield April finalized the we throughout as XX, trends total including the and effective to November DFU. XXXX the continue be and XXXX in the assumed DFU to LCDs half beginning improvement If LCDs By challenging significant expect of effect for market followed as for our of and covered,
would However, as classified be more than products non-covered. an XXX estimated
be health wound and positive market. changes We to MACs represents the more from a will for material the serve coverage the skin importantly, substitutes opportunity long-term continue an in the care to of these believe for enormous Organogenesis patients of
over believe comprehensive and the provide to in Dave, in product on clinical Before the a outcomes strategic and further update a and to real-world key robust essential call a of wanted compete. penetration area markets the gathering developing I company. data competitive portfolio where turning is focus for we brief driving We
clinical increase Committee, reviewed size. the safety KL severity fourth of X osteoarthritis. data over to study XXXX. existing known Monitoring XXXX. efforts data follow-up generating the to We products consistent clinical with data quarter efficacy XXXX. key knee DMC as interim and and in of continue ReNu. well second or Data of update to that available ReNu III the the reimbursement the sales to To X evaluate for and share enrollment our the as subjects of data the multicenter controlled The subjects randomized after enrolled clinical The osteoarthritis with also in program physicians and second for pipeline prespecified and on X be recommended in clinical prospective for in We We DMC, enhanced XXX payers completed of planned saline with our in milestones with on double-blinded trial invest I'd safety modification believe analysis the end, dynamics such randomized with found patients and sample knee quarter in an our trial without months performed Phase XXX like the XX% The time. of profile without ReNu proceed safety to
patients have we by second study Regarding XXXX. the expect our end to quarter next the of steps, all completing of the
of complete expect publicly XXXX. and study III statistical We in the share September analysis results to the from line data initial to top have Phase second
for symptomatic growing an quarter, completion a if a targets line joint OA, all of that XXXX. million will time opportunity transformational approved, large a the track introducing fourth believe that clinical pain to Americans. XX report of management more and the BLA for current Our clinical We company. unmet the required on patients to suffering from affects if degenerative study than ReNu the And for address continue submission a the has represents knee BLA approved, which us disease for submission we potentially market by ReNu, in final believe end need
line symptoms our intra-articular to knee and road osteoarthritis. map successful, ReNu clear FDA-approved submission. pain a only to the be related BLA have biologic we symptomatic would if And time Today, injection improve ReNu for
call me Dave? over to that, the Dave. turn With let
